Search - tctmd.com

Displaying 221 - 240 of 265

Sort: Relevancy | Date

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

News Daily News

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

Yael L. Maxwell

August 06, 2020

Higher Risk of HF After ACS for Women Previously on Beta-blockers

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

News Daily News

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

January 14, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

News Daily News

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

November 20, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

September 24, 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

August 20, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

News Conference News ESC Heart Failure 2019

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

May 28, 2019

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

May 09, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.